{"id":"nct:NCT06875973","kind":"trial","title":"Pelacarsen Roll-over Extension Program","authors":["Novartis Pharmaceuticals"],"author_count":1,"year":2025,"published":"2025-03-14","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT06875973","source_url":"https://clinicaltrials.gov/study/NCT06875973","archive_url":"https://space-kitty.com/papers/nct:NCT06875973","updated":"2026-10-14","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"This non-randomized, rollover extension study will provide post-trial access to pelacarsen (TQJ230) to participants who have successfully completed either of the double-blind parent studies (CTQJ230A12303 or CTQJ230A12304). Study has been terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Atherosclerotic Cardiovascular Disease"],"details":{"acronym":null,"status":"ACTIVE_NOT_RECRUITING","phase":"PHASE3","study_type":"INTERVENTIONAL","enrollment":599,"sponsor":"Novartis Pharmaceuticals","conditions":["Atherosclerotic Cardiovascular Disease"],"interventions":["DRUG: Pelacarsen (TQJ230)"],"start_date":"2025-05-19","start_date_type":"ACTUAL","primary_completion_date":"2030-12-08","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"cardiovascular-innovation","name":"Cardiovascular Therapeutics","domain_slug":"medicine"}],"cited_in_dossiers":[]}